Cardiolens Viewer® — now CE-marked under MDR

I truly believe that together with Hemolens Diagnostics we will develop a new standard that will allow us to apply the non-invasive FFR-CT diagnostic tool in patients with intermediate-risk coronary artery disease. These are patients who, considering the contraindications, would not be eligible for invasive diagnostic work-up.

With FFR-CT, Hemolens Diagnostics offers a promising new technology to detect anatomically and functionally significant coronary artery stenosis on the basis of non-invasive examinations: coronary computed tomography angiography (CCTA) and continuous non-invasive blood pressure (CNBP) monitoring. Methods based on measuring fractional flow reserve (FFR) from computed tomography scans of coronary arteries are recommended by international scientific associations.

I became involved in the Hemolens Diagnostics project because I believe that advancements in technology can redefine the limits of existing testing procedures and provide clinical practitioners with ever more detailed insights. Non-invasive methods are the future of medicine.